Rifasutenizol - TenNor Therapeutics
Alternative Names: TNP-2198Latest Information Update: 02 Dec 2024
Price :
$50 *
At a glance
- Originator Cumbre Pharmaceuticals
- Developer TenNor Therapeutics
- Class Antibacterials; Drug conjugates; Nitroimidazoles; Rifamycins
- Mechanism of Action DNA synthesis inhibitors; Protein 50S ribosomal subunit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Helicobacter infections
- Phase I Bacterial vaginosis
Most Recent Events
- 18 Nov 2024 Efficacy and adverse events data from a phase III trial in Helicobacter infections released by TenNor Therapeutics
- 16 Oct 2024 Rifasutenizol receives Fast track status from the US FDA for Helicobacter infections
- 16 Oct 2024 Rifasutenizol receives Qualified Infectious Disease Product (QIDP) status from the US FDA for Helicobacter infections